bacterpylori. Movement of a drug into mucus will be determined by its intragastric availability. Availability will depend upon various factors including the drug's behaviour in solution.
Gastric mucus plays an important role in mucosal protection. ' Disruption in the integrity of the blanket of mucus has been found in individuals with peptic ulcer.8"12 Helicobacter pylori present in gastric mucus of the stomach or duodenal gastric metaplasia is associated with gastritis and peptic ulceration.'3 22 Helicobacter pylori resides in gastric mucus but not within epithelial cells.2"24 It may play a role in mucin breakdown. [25] [26] [27] Eradication of Helicobacter pylori by colloidal bismuth subcitrate is followed by histological improvement of gastritis and healing of peptic ulcer.242829 If infection recurs, ulcer relapse is frequent, particularly after one year. 24 30 31 A combination of colloidal bismuth subcitrate with one or two antibiotics -fQr example, amoxycillin and/or metronidazole, is more successful than monotherapy in eradicating Helicobacter pylor 24323 Ulcer relapse after colloidal bismuth subcitrate and other antibiotics may be the result of a failure of the drug(s) to reach sufficient intramucus concentrations to eradicate Helico- bacterpylori. Movement of a drug into mucus will be determined by its intragastric availability. Availability will depend upon various factors including the drug's behaviour in solution.
It is not known whether non-infected and Helicobacter pylon infected mucus differ in their capacity to contain colloidal bismuth subcitrate and little is known on the behaviour of colloidal bismuth subcitrate in solution.
In this in vitro study we have examined the effect of Helicobacter pylon' infection on the capacity of gastric mucus to concentrate colloidal bismuth subcitrate and the behaviour ofcolloidal bismuth subcitrate in acidic solutions.
Methods

SPECIMENS
Mucus from 20 human stomachs was collected at necropsy within 24 hours of death. All persons (18- In separate experiments we observed the disintegration of commercial colloidal bismuth subcitrate tablets. Saline solutions were adjusted to In separate experiments, using unfiltered colloidal bismuth subcitrate solutions and no fine gauze mesh we found that a whitish precipitate was deposited on the mucus surface after the experiments, especially at low pH's; bismuth concentrations were up to five fold greater than bismuth levels obtained after using filtered colloidal bismuth subcitrate solutions.
COLLOIDAL BISMUTH SUBCITRATE SOLUBILITY Figure 1 shows percentages of colloidal bismuth subcitrate solubility estimated from bismuth concentrations in supernatant samples. Solubility in solution was >81% at pH 0.5 to 1-05; <50% at pH 1 1 to 3-25 and >88% at pH 3-75 to 6-25. Minimum solubility (<15%) occurred in the pH range 1 1 to 2-1. Two points of rapid change from high precipitation to high solubility can be described, one between pH 3-25 and 3-75 and the other between pH 1.05 and 1 1.
Half disintegration times for commercial colloidal bismuth subcitrate tablets are shown in Figure 2 . At pH 0 8, 1 0 and 1 *1, coated colloidal Figure 1 shows, at both pH's (3 75 to 6 25 and 1 0), colloidal bismuth subcitrate solubility will be favoured but, as speculated, the colloidal bismuth subcitrate forms in solution will be different. Further studies will be necessary to determine if the intragastric pH is important for a better success in eradicating Helicobacter pylori.
The ecologic niche for Helicobacterpylori is the gastric mucus. For any antibacterial agent to eradicate it, it must be able to penetrate the mucus layer in sufficient concentrations. We have shown that gastric mucus possesses the capacity to concentrate colloidal bismuth subcitrate and that this capacity is reduced when Helicobacter pylorn are present. In vivo, the reduced capacity of mucus to concentrate colloidal bismuth subcitrate may compromise the attainment of optimal intramucus colloidal bismuth subcitrate concentrations necessary for its bactericidal activity. The behaviour of colloidal bismuth subcitrate in acidic solutions suggests that the intragastric availability of the drug in solution may be low, further restricting satisfactory antibacterial intramucus concentrations. 
